Neoantigens Vaccines Can Bridge the Treatment Gap by Training the Immune System to Recognize Tumor Cells
As per BIS Research analysis, the neoantigen cancer vaccine market is projected to reach $1826.1 million by 2030 from $227.1 million in 2023, at a CAGR of 34.69%. Growth in this market is expected to be driven by the ever-rising patient pool of different cancers and significant investment in research for development for cancer neoantigen vaccines to fill in the current treatment gaps. However, there are significant challenges that are restraining the market growth. These challenges include the high cost of therapy (personalized cancer vaccines), manufacturing complications, and lack of therapeutic biomarkers and assays. The market is still at the nascent phase with more than two-thirds of the neovaccines in the early stages of development. However, few neovaccines companies such as OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, and Roche have positioned themselves to launch their neovaccines in the market within the upcoming years. That being said, the neovacc...